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A B S T R A C T
In the year 2003, the residents of Kamisu, Japan, were exposed to pentavalent organic arsenic diphenylarsinic
acid (DPAA[V]) via their normal drinking water. Following the exposure, they developed cerebellar and
brainstem symptoms. Although the relatively high dose of DPAA(V) is assumed to have caused their symptoms,
the relationship between the exposed dose of DPAA(V) and the level of their deposition in the central nervous
system (CNS) remains unclear. Using liquid chromatography–tandem mass spectrometry, we examined the
deposition of DPAA(V) and its pentavalent metabolites in the CNS tissues of Crl:CD(SD) rats following the ad-
ministration of DPAA(V) for 28 days. We found that the concentrations of DPAA(V) in the CNS were very high,
given a dose of 5.0 mg/kg/day. However, very low concentrations of DPAA(V) were detected at a dose of 0.3 or
1.2 mg/kg/day, suggesting the absence of a linear dose-response relationship between the dose and deposition of
DPAA(V). We also found that this non-linear relationship was commonly observed in various non-CNS tissues,
including the excretory system. Our study showed for the ﬁrst time the exact relationship between the dose and
tissue deposition of the organic arsenic following its subchronic administration.
1. Introduction
In the year 2003, unexplained symptoms were reported by patients
in Kamisu, Ibaraki Prefecture, Japan. Organic arsenic compounds were
identiﬁed in the wells of their drinking water as the cause of their
symptoms (Ishii et al., 2004). The organic arsenic detected in the
drinking well water was determined to be diphenylarsinic acid
(DPAA[V]), a pentavalent organic arsenic compound used in the
synthesis of chemical weapons during World War II (Kurata, 1980).
Further analyses revealed that DPAA(V) had leaked from concrete-like
blocks to the bottom of the aquifer and thus had contaminated the
drinking well water (Watanabe et al., 2011). The water from one of the
wells contained as much as 4.5 mg As/L of DPAA(V), which is 450 times
higher than the concentration of the drinking water quality standards
approved by the Ministry of Health, Labour and Welfare, Japan
(Kinoshita et al., 2005; Shibata et al., 2005).
Organic arsenic monomethylarsonic acid (MMA[V]) and
dimethylarsinic acid (DMA[V]) are known to be metabolites of in-
organic arsenic (iAs). The metabolism and genotoxicity of these two
organic arsenic compounds have been well studied since the early
1980s (Cohen et al., 2006). However, DPAA(V) is not a natural product.
Therefore, our knowledge of its toxicokinetics has been quite limited.
Residents exposed to DPAA(V) experienced progressive cerebellar,
brainstem, and temporal and occipital lobe symptoms, but not periph-
eral neuropathies (Ishii et al., 2004). Analyses of the cerebral blood
ﬂow with single photon emission computed tomography revealed a
decrease in the blood ﬂow in the occipital lobe and cerebellar vermis in
DPAA(V)-exposed residents (Ishii and Tamaoka, 2015).
To date, the relationship between the exposed dose of DPAA(V) and
the level of its deposition in the central nervous system (CNS) has been
unclear. Regarding other organic arsenic compounds, there has been
one report using rodents to examine the relationship between sub-
chronic exposure and tissue concentration. They measured the con-
centration of DMA(V) in body ﬂuids and 4 tissues at 14 days after the
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T
administration of DMA(V) and found that the relationship between the
dose of DMA(V) administered and its amount in tissues was nearly
linear (Adair et al., 2007).
In the present study, we orally administered DPAA(V) to rats at
incremental doses for 28 days. After the administration, the amounts of
DPAA(V) deposition in 11 tissues were then measured by liquid chro-
matography–tandem mass spectrometry (LC–MS/MS). Furthermore, we
measured the concentrations of pentavalent phenylarsonic acid
(PAA[V]) and phenylmethylarsinic acid (PMAA[V]), which are known
to be major metabolites of DPAA(V).
2. Materials and methods
2.1. Arsenic
Phenyl arsenic compounds (DPAA[V], diphenylmethylarsine oxide
[DPMAO], PMAA[V], phenyldimethylarsine oxide [PDMAO], and
PAA[V]) were purchased from Tri Chemical Laboratories (Yamanashi,
Japan) and stored at 4 °C in the dark. Stable radioactive isotopes (13C-
DPAA[V], 13C-DPMAO, 13C-PMAA[V], 13C-PDMAO, and 13C-PAA[V])
were produced by Hayashi Pure Chemical Industries (Osaka, Japan).
2.2. Animals
Twenty-eight Crj:CD(SD) rats (6 weeks old; 12 males and 12 fe-
males) were obtained from Charles River Laboratories Japan, Inc.
(Kanagawa, Japan). The administration of DPAA(V) to the rats and
collection of their tissues were done at LSI Medience Corporation
(Tokyo, Japan). All of the experiments were conducted according to the
Guidelines for Proper Conduct of Animal Experiments, which were
approved by the Science Council of Japan.
2.3. Experiments and the sampling of tissues
The rats were divided into four groups; each group consisted of 3
males and 3 females. Based on the previous evaluation that estimatedTa
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Fig. 1. Eﬀect of 28-day exposure to DPAA(V) on body weight of rats. Body weights of
male (A) and female (B) rats were measured on days 1, 8, 15, 22, and 28 during their
exposure to 0–5.0 mg/kg/day of DPAA(V). Symbols show mean values, and vertical lines
indicate SEM. n= 3, for each group.
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the exposed dose for the Kamisu cohort who developed CNS symptoms
to be 0.62–0.93 mg/kg/day (Ishii et al., 2014), the rats were orally
administered 0.3, 1.2, and 5.0 mg/kg/day of DPAA(V) in this study.
DPAA(V) dissolved in distilled water was administered through an oral
gastric tube for 28 days to 3 groups at each dose (see Table 1). Sup-
plemental water was not administered to the control group.
After the animals were euthanized, tissue specimens (11 total) were
excised and collected (Table 1). We selected these tissues with a focus
on the CNS based on our previous ﬁndings using cynomolgus monkeys
(Masuda et al., 2017). Five tissues were derived from the CNS (frontal-
parietal lobe, temporal-occipital lobe, cerebellum, brainstem, and
spinal cord). We also collected samples from the peripheral nervous
system (PNS; sciatic nerve), excretory system (liver and kidneys),
lymphatic system (spleen), respiratory system (lungs), and the muscular
system (iliopsoas muscle). The samples were then frozen in liquid ni-
trogen and stored at −80 °C.
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0.0
2.0e4
4.0e4
3.55
0.0
1.0e4
1.7e4
6.06
0
2000
4000
5295
6.05
0
2000
4000
5790
5.71
0
2000
4000
5.67
0.0
5.0e4
9.2e4
10.80
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0
0.0
2.0e4
4.0e4
11.49
PDMAO
PMAA(V)
m/z 201 > 77
m/z 201 > 94
Time (min)
In
te
ns
ity PAA(V)
m/z 203 > 77
m/z 203 > 185
DPMAO
m/z 261 > 154
m/z 263 > 152
DPAA(V)
Fig. 2. A selected reaction monitoring chromatogram for phenyl arsenic compounds in aqueous solution. DPAA(V), DPMAO, PAA(V), PMAA(V), and PDMAO solutions (4 μL each) were
injected into an LC–MS/MS system ﬁtted with an Atlantis T3 column.
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2.4. Extraction of phenyl arsenic compounds
A Teﬂon homogenizer (Ikemoto Scientiﬁc Technology Co., Ltd.,
Tokyo, Japan) was used to process tissue samples, and 20% of each
homogenate was prepared in 50 mM ammonium acetate solution. The
separation of ﬂuids from the tissues was performed using an ultra-
centrifuge (105,000 ×g) at 4 °C. Subsequently, 0.1 mL of bovine serum
albumin (80 mg/mL; Takara Bio Inc., Shiga, Japan), 1 mL of 4 M NaOH,
and 0.9 mL of H2O were added to 0.1 g of the precipitates prepared
above. The radioactive isotopes 13C-DPAA(V), 13C-DPMAO, 13C-
PMAA(V), 13C-PDMAO, and 13C-PAA(V) (each 100 ppb) were added to
the solutions and incubated at 90 °C for 3 h. After adding diethyl ether
(Wako Pure Chemical Industries, Ltd.: > 99.5%), the mixed solution
was centrifuged for 5 min to extract phenyl arsenic compounds with
diethyl ether. Using a stream of dry N2, the diethyl ether was removed
from the phenyl arsenic compounds. After the addition of nitric acid
(Wako Pure Chemical Industries, Ltd.), the phenyl arsenic compounds
were completely dissolved in 10 mL of H2O.
2.5. Analysis of phenyl arsenic
Agilent 1200 Series (Agilent Technologies, Santa Clara, CA) coupled
with 4000 Q TRAP LC–MS/MS System (AB Sciex, Framingham, MA)
were used in this study. Chromatographic separation was achieved
using Atlantis T3 columns (150 × 2.1 mm i.d., 3-μm thickness, Waters
Corporation, Milford, MA) at 40 °C. The sample solutions (4 μL) were
injected into the column. In the columns, elution was performed using a
linear gradient of 0.1% formic acid (Wako Pure Chemical Industries,
Ltd., 99.0%) in water [A] with 0.1% formic acid in methanol-water
(1:9, v/v) [B] as follows: 80 to 10% [A]: 20 to 90% [B] (7.5 min), 10%
[A]: 90% [B] (2-min hold), 10 to 80% [A]: 90 to 20% [B] (0.5 min),
80% [A]: 20% [B] (10-min hold). The ﬂow rate was maintained at
0.2 mL/min. Electrospray ionization was performed in positive ioniza-
tion mode. The [M + H]+ ions of the targeted compounds (DPAA[V],
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The approximation curve obtained from 3 measured points shows the correlation between the administered doses and the average concentrations of DPAA(V) (ng As/g) in each CNS tissue
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13C-DPAA[V], DPMAO, 13C-DPMAO, PMAA[V], 13C-PMAA[V],
PDMAO, 13C-PDMAO, PAA[V], 13C-PAA[V]) were selected as the pre-
cursor ions. Selected reaction monitoring (SRM) was used to quantify
each compound. The precursor and product ions were monitored. The
collision energies of the compounds were as follows: m/z 263 > 152,
35 eV for DPAA(V); m/z 275 > 158, 35 eV for 13C-DPAA(V); m/z
261 > 154, 35 eV for DPMAO; m/z 273 > 166, 35 eV for 13C-
DPMAO; m/z 203 > 77, 30 eV for PAA(V); m/z 209 > 83, 30 eV for
13C-PAA(V); m/z 201 > 77, 50 eV for PMAA(V); m/z 207 > 83,
50 eV for 13C-PMAA(V); m/z 199 > 169, 30 eV for PDMAO; and m/z
205 > 175, 30 eV for 13C-PDMAO. To determine the compounds with
greater precision, we monitored the other product ions as well: m/z
203 > 185 for PAA(V); m/z 201 > 94 for PMAA(V). The MS/MS
parameters for the analysis were as follows: spray voltage, 4500 V;
curtain gas pressure, 20 Pa; vaporizing temperature, 700 °C; collision
gas pressure, 8 Pa. Data acquisition and instrument control were per-
formed using the Analyst ver. 1.4 software (AB Sciex).
2.6. Statistical analyses
The Tukey–Kramer method was used for multiple group compar-
isons. The Kruskal-Wallis test was used for nonparametric statistics.
Statistical analyses were performed using the JMP software program
(version 5.12-J, SAS Institute Inc., Cary, NC, USA). p-Values of< 0.05
were considered statistically signiﬁcant. The JMP software program
(version 5.12-J) was also used to perform a curvilinear regression
analysis, which allowed us to approximate the quadratic curves.
3. Results
3.1. General observations and weight changes
The 5.0 mg/kg/day of DPAA(V)-exposed group seemed to be less
active than the control group. Additional symptoms including tremors
and gait disturbance were observed in this group, as well as a decrease
in mean body weight gain regardless of gender (Fig. 1). However, the
body weight in the 5.0 mg/kg/day of DPAA(V)-exposed group was not
signiﬁcantly diﬀerent from that in the other groups after 28-day ex-
posure both genders (Kruskal-Wallis test, p= 0.0765–0.0809).
3.2. Liquid chromatography–tandem mass spectrometry
DPAA(V) and its related metabolites were identiﬁed in the tissue
samples by LC–MS/MS using the isotope dilution method. These phenyl
arsenic compounds were well separated under the LC conditions using
Atlantis T3 columns. The [M + H]+ ions of the target compounds were
carefully observed by electrospray ionization. The sample solutions
(4 μL) were injected into the LC–MS/MS system to achieve optimal
detection sensitivity. During SRM, the product ions and collision en-
ergies were selected by optimizing the conditions in the product ion
scan spectra of the target precursor ions. A typical SRM chromatogram
for the control is shown in Fig. 2. Calibration curves were prepared for
the peak area ratios of the target compounds of the corresponding
13C–labeled internal standards on the respective SRM chromatograms.
If positive peaks were observed in SRM, the presence of the corre-
sponding product ion peaks was tested for PAA(V), PMAA(V), and
PDMAO. This provides a deﬁnitive conﬁrmation of the presence of
PAA(V), PMAA(V), and PDMAO, as these highly hydrophilic com-
pounds typically suﬀer from severe interference from the biological
matrix components in sample extracts during LC separation and MS/MS
detection.
3.3. Quantitative analysis of DPAA(V) in the CNS tissues
The exposed dose for the Kamisu residents who experienced CNS
neuropathies has been estimated at 0.62–0.93 mg/kg/day (Ishii et al.,Ta
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2014). Based on this previous evaluation, rats were administered either
0.3, 1.2, or 5.0 mg/kg/day of DPAA(V) orally in the present study. The
control group was administered water without DPAA(V). After admin-
istering DPAA(V) for 28 days, the CNS tissues (frontal-parietal lobe,
temporal-occipital lobe, cerebellum, brainstem, and spinal cord) were
collected, and the concentration of DPAA(V) was measured via LC–MS/
MS (Table 1). The relationship between the exposed dose of DPAA(V)
and its concentration is shown in Fig. 3. No DPAA(V) was detected in
the tissues analyzed from rats in the control group (data not shown).
The concentrations of DPAA(V) in all of the CNS tissues showed a
gradual increase with the dose that was administered. However, al-
though DPAA(V) concentrations rose in the group administered
5.0 mg/kg/day of DPAA(V), it was not in a dose-dependent manner
(Fig. 3). Namely, the relationship between doses and tissue con-
centrations of DPAA(V) was not linear in any of the CNS tissue speci-
mens.
3.4. Quantitative analysis of DPAA(V) in various non-CNS tissues
To examine whether the rapid increase of DPAA(V) concentrations
at 5.0 mg/kg/day of DPAA(V) administration may be characteristic of
the CNS tissues, we selected tissues other than CNS ones (sciatic nerve,
liver, kidneys, spleen, lungs, iliopsoas muscle) and measured their
DPAA(V) concentrations after administering DPAA(V) for 28 days
(Table 2). We found the same trend in the relationship between doses
and tissue concentrations of DPAA(V), i.e. the absence of a linear dose-
response relationship following administration (Fig. 4). In addition, we
compared the concentration of DPAA(V) in the CNS tissues with those
in the other tissues. At 5.0 mg/kg/day of DPAA(V) administration, we
found that the average concentration of DPAA(V) in the CNS tissues was
signiﬁcantly higher than those in the other tissues (*p < 0.001; Fig. 5).
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Fig. 4. The curves ﬁt for exponential approximation show a correlation between the administered doses and the average concentrations of DPAA(V) (ng As/g) in various non-CNS tissues.
The approximation curve obtained from 3 measured points shows the correlation between the administered doses and the average concentrations of DPAA(V) (ng As/g) in each tissue
after administering DPAA(V) (0.3–5.0 mg/kg/day) for 28 days. The vertical line shows the concentration of DPAA(V), while the horizontal one shows the amount of DPAA(V) ad-
ministered. The average values± SEM are shown using horizontal lines.
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3.5. Sex diﬀerences in the tissue accumulation of DPAA(V)
We further analyzed the sex diﬀerences in the tissue accumulation
of DPAA(V). In the 0.3 mg/kg/day of DPAA(V)-exposed group, the
DPAA(V) concentrations in a part of the male tissues except for the
sciatic nerve and the kidney were signiﬁcantly higher than those in the
female tissues. The signiﬁcant diﬀerences in DPAA(V) concentration
between the male and female tissues were as follow: the temporal-oc-
cipital lobe (p= 0.0423), brainstem (p= 0.0365), spinal cord
(p= 0.0200), liver (p= 0.0231), kidneys (p= 0.000900), and lungs
(p= 0.0265). In the 1.2 mg/kg/day of DPAA(V)-exposed group, the
signiﬁcant diﬀerences between the concentrations of male and female
tissues were as follow: the frontal-parietal lobe (p= 0.00660), cere-
bellum (p= 0.00820), and kidneys (p= 0.0282). Except for the
kidney, the DPAA(V) concentrations in the male tissues were sig-
niﬁcantly higher than those in the female tissues. In the group exposed
to 5.0 mg/kg/day of DPAA(V), we could not detect any signiﬁcant
diﬀerence in the concentrations of DPAA(V) between male and female
tissues.
3.6. Quantitative analysis of PMAA(V) and PAA(V) in the rat tissues
PMAA(V) and PAA(V) are known to be major metabolites of
DPAA(V). Using LC–MS/MS, we measured the concentrations of
PMAA(V) and PAA(V) in the same tissues from one male rat of each
group. We detected very small amounts of PMAA(V) and PAA(V) in the
11 tissues after administering DPAA(V) (Table 3).
4. Discussion
In the present study, we measured the concentration of DPAA(V) in
5 CNS and 6 other non-CNS tissues after 28 days of DPAA(V) admin-
istration. When DPAA(V) was administered to rats at 5.0 mg/kg/day,
the amount of DPAA(V) in each tissue rapidly increased as compared
with that at 1.2 mg/kg/day, i.e. the relationship between the dose of
DPAA(V) administered and its amount in tissues was nonlinear after
high-dose DPAA(V) exposure.
There are two possible explanations for the rapid DPAA(V) accu-
mulation after a high-dose exposure. Since DPAA(V) is known to be
excreted in urine and feces via the liver and kidneys in mammals
(Kobayashi et al., 2008; Kobayashi and Hirano, 2013), one possibility is
renal impairment due to the exposure to DPAA(V). However, no chronic
nephropathy was reported in the kidneys of DPAA(V)-exposed rats
(Yamaguchi et al., 2017), suggesting that DPAA(V) may not play a role
as a nephrotoxin. Thus, it is possible that DPAA(V) accumulated in the
kidneys at concentrations that surpassed the rate of excretion by the
kidneys.
The second potential explanation is the impairment of the liver
function. Our histopathological observations in monkeys have shown
that the subchronic administration of DPAA(V) induced hepatic
changes, such as atypical ductular proliferation and cell inﬁltration in
Glisson's capsules (unpublished observation). A separate study using
rats also revealed that DPAA(V) is toxic in bile ducts when administered
for 52 days (Yamaguchi et al., 2017). It is likely that the impairment of
the liver function might induce a decrease in DPAA(V) excretion and
subsequently cause DPAA(V) to accumulate rapidly in the tissues. To
clarify the toxic mechanism of DPAA(V) in vivo, further analyses will be
required including determination of the principal cause of the rapid
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Table 3
PMAA(V) and PAA(V) concentration in the tissues of rats after oral administration of DPAA(V).
PMAA(V) and PAA(V) after 0.3–5.0 mg/kg/day of DPAA(V) administration (average ng As/g ± SEM)
0.3 mg/kg/day 1.2 mg/kg/day 5.0 mg/kg/day
PMAA(V) PAA(V) PMAA(V) PAA(V) PMAA(V) PAA(V)
Central nervous system Frontal-parietal lobe 23.3 ND 22.1 ND 23.4 40.5
Temporal-occipital lobe ND ND ND ND 17.1 17.7
Cerebellum ND ND ND ND 16.1 37.9
Brainstem ND ND ND ND 16.7 72.8
Spinal cord ND ND ND ND 30.0 15.8
Peripheral nervous system Sciatic nerve ND ND ND ND 18.4 4.07
Excretory system Liver ND ND 1.94 1.63 64.1 20.6
Kidney ND ND 1.93 1.81 93.2 41.3
Lymphatic system Spleen 1.25 ND 5.60 ND 283 18.7
Respiratory system Lung ND ND 2.82 ND 152 12.0
Muscular system Iliopsoas muscle ND ND ND ND 32.7 5.38
ND; not detected.
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DPAA(V) accumulation after high-dose exposure.
The present study showed that the concentrations of DPAA(V) in the
CNS tissues at 5.0 mg/kg/day of DPAA(V) administration were sig-
niﬁcantly higher than those in the other tissues. Our previous results
showed that DPAA(V) was detected in the cerebrospinal ﬂuid obtained
from both the Kamisu residents and DPAA(V)-exposed monkeys (Ishii
et al., 2014; Masuda et al., 2017). These ﬁndings suggest that DPAA(V)
can pass through the blood-brain barrier (BBB) in primates. Although
we did not examine the DPAA(V) concentration in the cerebrospinal
ﬂuid in the present study, the amount of DPAA(V) in the rat CNS sug-
gests that DPAA(V) may also pass through the BBB of rodents and enter
the CNS. In the previous study, we showed that DPAA(V) was barely
excreted from the CNS tissues after passing through the BBB in monkeys
(Masuda et al., 2017). Along the same lines, it is highly likely that the
low excretion capacity of DPAA(V) may result in a large amount of
DPAA(V) deposition in the rat CNS.
The estimated dose of DPAA(V) exposure per day (0.93 mg/kg/day)
in the Kamisu cohort (Ishii et al., 2014) is smaller than that in this
study. However, the residents in Kamisu with neurologic symptoms had
been drinking the contaminated water at that concentration daily
for> 3 years, whereas we set the duration of exposure in our present
study to a much shorter one (28 days). Considering the short duration
of exposure, it is reasonable in this study to have prepared a larger dose
for the daily exposure than in the Kamisu cohort. Prior to this study, a
preliminary experiment of oral administration of DPAA(V) to rats at
doses of 1.7–170 mg/kg/day for 14 days was carried out (data not
shown). Based on the results of that preliminary experiment, we
decided to set 5.0 mg/kg/day of DPAA(V) as a high dose; because we
expected that rats would not die during the 28-day administration
period. If the duration of exposure is not taken into consideration, the
DPAA(V) doses of 0.3–1.2 mg/kg/day at which the linear DPAA(V)
accumulation was shown correspond to the dose of daily exposure in
Kamisu residents. The absence of remarkable symptoms in Kamisu re-
sidents other than the CNS ones predicted that there might be no rapid
accumulation in the tissues other than the CNS by DPAA(V) exposure at
0.93 mg/kg/day. Results obtained from the doses of 0.3–1.2 mg/kg/
day in this study support this prediction. Our previous results using
monkeys showed that the clearance rate of DPAA(V) in the CNS is quite
low compared with that in other tissues, resulting in the high accu-
mulation of DPAA(V) in the CNS tissues for a long period (Masuda
et al., 2017). Along the same line, in the case of Kamisu residents, the
long-term exposure to relatively low doses of DPAA(V) might have in-
duced the high accumulation of DPAA(V) only in the CNS, resulting in
the onset of their neurological symptoms.
In this study, we analyzed DPAA(V) accumulation in the tissues
following its administration to equal numbers of male and female rats.
Several tissues showed sex diﬀerences in DPAA(V) accumulation in
each group, and the results obtained were divided into cases where
either male or female concentrations were higher. There is room for
argument about the results obtained in this research because we used a
limited number of samples. Further detailed analysis of sex diﬀerences
in DPAA(V) accumulation may be required in the future.
To our knowledge, the present study is the ﬁrst report that com-
prehensively analyzed the relationship between the dose and tissue
condensation of compounds of organic arsenic(V) via the high-sensi-
tivity quantitative method of LC–MS/MS. We hope our comprehensive
results will be utilized as the fundamental data of tissue distributions of
DPAA(V) and thus may contribute to the future treatment of DPAA(V)-
exposed patients and the prevention of arsenic poisoning in humans.
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